UniProt ID | RANB9_HUMAN | |
---|---|---|
UniProt AC | Q96S59 | |
Protein Name | Ran-binding protein 9 | |
Gene Name | RANBP9 | |
Organism | Homo sapiens (Human). | |
Sequence Length | 729 | |
Subcellular Localization |
Cytoplasm . Nucleus . Cell membrane Peripheral membrane protein . The unphosphorylated form is predominantly cytoplasmic. A phosphorylated form is associated with the plasma membrane. |
|
Protein Description | May act as an adapter protein to couple membrane receptors to intracellular signaling pathways. May be involved in signaling of ITGB2/LFA-1 and other integrins. Enhances HGF-MET signaling by recruiting Sos and activating the Ras pathway. Enhances dihydrotestosterone-induced transactivation activity of AR, as well as dexamethasone-induced transactivation activity of NR3C1, but not affect estrogen-induced transactivation. Stabilizes TP73 isoform Alpha, probably by inhibiting its ubiquitination, and increases its proapoptotic activity. Inhibits the kinase activity of DYRK1A and DYRK1B. Inhibits FMR1 binding to RNA.. | |
Protein Sequence | MSGQPPPPPPQQQQQQQQLSPPPPAALAPVSGVVLPAPPAVSAGSSPAGSPGGGAGGEGLGAAAAALLLHPPPPPPPATAAPPPPPPPPPPPASAAAPASGPPAPPGLAAGPGPAGGAPTPALVAGSSAAAPFPHGDSALNEQEKELQRRLKRLYPAVDEQETPLPRSWSPKDKFSYIGLSQNNLRVHYKGHGKTPKDAASVRATHPIPAACGIYYFEVKIVSKGRDGYMGIGLSAQGVNMNRLPGWDKHSYGYHGDDGHSFCSSGTGQPYGPTFTTGDVIGCCVNLINNTCFYTKNGHSLGIAFTDLPPNLYPTVGLQTPGEVVDANFGQHPFVFDIEDYMREWRTKIQAQIDRFPIGDREGEWQTMIQKMVSSYLVHHGYCATAEAFARSTDQTVLEELASIKNRQRIQKLVLAGRMGEAIETTQQLYPSLLERNPNLLFTLKVRQFIEMVNGTDSEVRCLGGRSPKSQDSYPVSPRPFSSPSMSPSHGMNIHNLASGKGSTAHFSGFESCSNGVISNKAHQSYCHSNKHQSSNLNVPELNSINMSRSQQVNNFTSNDVDMETDHYSNGVGETSSNGFLNGSSKHDHEMEDCDTEMEVDSSQLRRQLCGGSQAAIERMIHFGRELQAMSEQLRRDCGKNTANKKMLKDAFSLLAYSDPWNSPVGNQLDPIQREPVCSALNSAILETHNLPKQPPLALAMGQATQCLGLMARSGIGSCAFATVEDYLH | |
Overview of Protein Modification Sites with Functional and Structural Information | ||
* ASA = Accessible Surface Area
Locations | Modification | Substrate Peptides & Secondary Structure |
ASA (%) | Reference | Orthologous Protein Cluster |
---|---|---|---|---|---|
64 (in isoform 2) | Ubiquitination | - | 7.85 | 21890473 | |
104 (in isoform 2) | Ubiquitination | - | 26.50 | 21890473 | |
119 | Ubiquitination | PGPAGGAPTPALVAG CCCCCCCCCCHHCCC | 42.04 | - | |
168 | Phosphorylation | QETPLPRSWSPKDKF CCCCCCCCCCCCCCC | 29.93 | 28464451 | |
170 | Phosphorylation | TPLPRSWSPKDKFSY CCCCCCCCCCCCCCE | 24.26 | 24719451 | |
172 | Ubiquitination | LPRSWSPKDKFSYIG CCCCCCCCCCCCEEE | 68.95 | - | |
174 | Ubiquitination | RSWSPKDKFSYIGLS CCCCCCCCCCEEEEC | 42.19 | - | |
174 | Acetylation | RSWSPKDKFSYIGLS CCCCCCCCCCEEEEC | 42.19 | 25953088 | |
176 | Ubiquitination | WSPKDKFSYIGLSQN CCCCCCCCEEEECCC | 22.91 | - | |
177 | Phosphorylation | SPKDKFSYIGLSQNN CCCCCCCEEEECCCC | 11.35 | 28464451 | |
181 | Phosphorylation | KFSYIGLSQNNLRVH CCCEEEECCCCEEEE | 26.16 | - | |
183 | Ubiquitination | SYIGLSQNNLRVHYK CEEEECCCCEEEEEC | 46.24 | - | |
189 | Phosphorylation | QNNLRVHYKGHGKTP CCCEEEEECCCCCCH | 18.79 | - | |
197 | Ubiquitination | KGHGKTPKDAASVRA CCCCCCHHHCCCHHC | 66.29 | - | |
216 | Ubiquitination | PAACGIYYFEVKIVS CCCCEEEEEEEEEEE | 7.43 | - | |
304 (in isoform 2) | Ubiquitination | - | 10.25 | - | |
308 (in isoform 2) | Ubiquitination | - | 7.44 | - | |
348 | Ubiquitination | YMREWRTKIQAQIDR HHHHHHHHHHHHHCC | 25.01 | - | |
405 | Acetylation | LEELASIKNRQRIQK HHHHHHHCCHHHHHH | 43.51 | 19608861 | |
405 (in isoform 1) | Ubiquitination | - | 43.51 | 21890473 | |
405 | Ubiquitination | LEELASIKNRQRIQK HHHHHHHCCHHHHHH | 43.51 | 21906983 | |
412 | Ubiquitination | KNRQRIQKLVLAGRM CCHHHHHHHHHCCCH | 37.89 | - | |
412 | Acetylation | KNRQRIQKLVLAGRM CCHHHHHHHHHCCCH | 37.89 | 25953088 | |
416 | Ubiquitination | RIQKLVLAGRMGEAI HHHHHHHCCCHHHHH | 8.96 | - | |
420 | Ubiquitination | LVLAGRMGEAIETTQ HHHCCCHHHHHHHHH | 21.59 | - | |
443 | Phosphorylation | RNPNLLFTLKVRQFI HCCCEEEEEEHHHHH | 26.16 | - | |
445 | Ubiquitination | PNLLFTLKVRQFIEM CCEEEEEEHHHHHHH | 32.11 | 21890473 | |
445 (in isoform 1) | Ubiquitination | - | 32.11 | 21890473 | |
445 | Ubiquitination | PNLLFTLKVRQFIEM CCEEEEEEHHHHHHH | 32.11 | 21890473 | |
467 | Phosphorylation | VRCLGGRSPKSQDSY EEECCCCCCCCCCCC | 39.70 | 25159151 | |
470 | Phosphorylation | LGGRSPKSQDSYPVS CCCCCCCCCCCCCCC | 42.47 | 23663014 | |
473 | Phosphorylation | RSPKSQDSYPVSPRP CCCCCCCCCCCCCCC | 24.57 | 30266825 | |
474 | Phosphorylation | SPKSQDSYPVSPRPF CCCCCCCCCCCCCCC | 18.88 | 23927012 | |
477 | Phosphorylation | SQDSYPVSPRPFSSP CCCCCCCCCCCCCCC | 15.64 | 19664994 | |
482 | Phosphorylation | PVSPRPFSSPSMSPS CCCCCCCCCCCCCCC | 43.98 | 23401153 | |
483 | Phosphorylation | VSPRPFSSPSMSPSH CCCCCCCCCCCCCCC | 22.75 | 23401153 | |
485 | Phosphorylation | PRPFSSPSMSPSHGM CCCCCCCCCCCCCCC | 33.56 | 23401153 | |
487 | Phosphorylation | PFSSPSMSPSHGMNI CCCCCCCCCCCCCCH | 27.82 | 29255136 | |
489 | Phosphorylation | SSPSMSPSHGMNIHN CCCCCCCCCCCCHHC | 25.93 | 29255136 | |
499 | Phosphorylation | MNIHNLASGKGSTAH CCHHCCCCCCCCCCC | 44.17 | 23927012 | |
503 | Phosphorylation | NLASGKGSTAHFSGF CCCCCCCCCCCCCCC | 26.38 | - | |
508 | Phosphorylation | KGSTAHFSGFESCSN CCCCCCCCCCCCCCC | 32.48 | 28555341 | |
531 | Ubiquitination | QSYCHSNKHQSSNLN HHHHCCCCCCCCCCC | 46.14 | - | |
534 | Phosphorylation | CHSNKHQSSNLNVPE HCCCCCCCCCCCCCH | 22.40 | 27080861 | |
535 | Phosphorylation | HSNKHQSSNLNVPEL CCCCCCCCCCCCCHH | 38.47 | 27080861 | |
544 | Phosphorylation | LNVPELNSINMSRSQ CCCCHHHHHCCCHHH | 28.15 | 28555341 | |
548 | Phosphorylation | ELNSINMSRSQQVNN HHHHHCCCHHHHHCC | 25.05 | 28555341 | |
550 | Phosphorylation | NSINMSRSQQVNNFT HHHCCCHHHHHCCCC | 20.05 | - | |
568 | Phosphorylation | VDMETDHYSNGVGET CCCCCCCCCCCCCCC | 13.47 | - | |
596 | Phosphorylation | HEMEDCDTEMEVDSS CCCCCCCCEEECCHH | 43.49 | - | |
603 | Phosphorylation | TEMEVDSSQLRRQLC CEEECCHHHHHHHHC | 28.86 | 17525332 | |
613 | Phosphorylation | RRQLCGGSQAAIERM HHHHCCCCHHHHHHH | 11.26 | - |
Modified Location | Modified Residue | Modification | Function | Reference | ||
---|---|---|---|---|---|---|
Oops, there are no descriptions of PTM sites of RANB9_HUMAN !! |
* Distance = the distance between SAP position and PTM sites.
Modified Location | Modification | Variant Position (Distance <= 10) |
Residue Change | SAP | Related Disease | Reference |
---|---|---|---|---|---|---|
Oops, there are no SNP-PTM records of RANB9_HUMAN !! |
Kegg Disease | ||||||
---|---|---|---|---|---|---|
There are no disease associations of PTM sites. | ||||||
OMIM Disease | ||||||
There are no disease associations of PTM sites. | ||||||
Kegg Drug | ||||||
There are no disease associations of PTM sites. | ||||||
DrugBank | ||||||
There are no disease associations of PTM sites. |
loading...
Acetylation | |
Reference | PubMed |
"Lysine acetylation targets protein complexes and co-regulates majorcellular functions."; Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M., Walther T.,Olsen J.V., Mann M.; Science 325:834-840(2009). Cited for: ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-405, AND MASS SPECTROMETRY. | |
Phosphorylation | |
Reference | PubMed |
"ATM and ATR substrate analysis reveals extensive protein networksresponsive to DNA damage."; Matsuoka S., Ballif B.A., Smogorzewska A., McDonald E.R. III,Hurov K.E., Luo J., Bakalarski C.E., Zhao Z., Solimini N.,Lerenthal Y., Shiloh Y., Gygi S.P., Elledge S.J.; Science 316:1160-1166(2007). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-603, AND MASSSPECTROMETRY. |